All News

Pills_0.jpg

Polypharmacy Increased in Psoriatic Arthritis

Jack Cush, MD

Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.

Read Article
DMARDs,biologics,RA

Cost-Effective Use of Biological and Targeted Synthetic DMARDs

Jack Cush, MD

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Read Article
RheumNow Podcast square

Big Time Vasculitis (3.10.2023)

Jack Cush, MD

Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?

Read Article
pso.PsA_.NPF_.jpg

Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Jack Cush, MD

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article
RheumNow Podcast square

NSAIDs in Pregnancy (3.3.2023)

Jack Cush, MD

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

Read Article
Why JAKinibs in PsA ?! By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Also inflammatory bowel disease and most recently Upadacitinib for crohns disease. https://t.co/loUgJNUsKT
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Jaks are every where in Psoriatic disease domains, By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Good news, especially with Updacitinib recently and Crohn’s disease ( full package). https://t.co/nlBWJhzpLp
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
⚠️Only 12-43% of #PsA patients achieved remission or very low disease activity From systematic review in RWE presented by @DrLauraCoates #RNL2023

Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)

Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative @DrLauraCoates at #RNL2023 @Rheumnow https://t.co/hA7JDR7Zyh
Eric Dein ericdeinmd ( View Tweet)
I love a good graphic. Check out @DrLauraCoates’ review of the impact of MDA in PSAID scores in PsA. #RNL2023 @RheumNow https://t.co/iQYuLQobXL
Dr. Rachel Tate uptoTate ( View Tweet)
Treat to target in PSA: What's difference in our outcome scores? DAPSA: includes CRP MDA: includes enthesitis, skin, function Both metrics include Tender/Swollen jt counts, and pt pain/global Presented by @DrLauraCoates at #RNL2023 @RheumNow https://t.co/7i5m70HGiz
Eric Dein ericdeinmd ( View Tweet)
Dr. Laura Coates presents - Is remission in PsA attainable? systematic review: 12-43% achieved very low disease activity or remission #RNL2023 @RheumNow https://t.co/flfpzc7B4p
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 @RheumNow @DrLauraCoates: patients & physicians do not agree on what is remission in PsA Patients global scores: largely driven by pain and fatigue, not on joint counts Remission in PsA allows for disease control on Rx- not just drug-free remission, often not sustained https://t.co/Hr2uuWDAfr
Eric Dein ericdeinmd ( View Tweet)
Dr. Stanley Cohen on JAKinibs: Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions @RheumNow #RNL2023 https://t.co/3ZZHr0akrR
Robert B Chao, MD doctorRBC ( View Tweet)
29 pts w/PsA Sine Psoriasis: 16F/13M, mean age 45 yrs w/ PsA ~6.2 yrs. 54% had 1st-degree relatives with PsA. 66% had DIP arthritis, 39% polyarticular, 36% oligoarticular, 25% were axial. Nail findings seen in 89%, enthesitis 59%, dactylitis 62% https://t.co/FPAqosYr9C https://t.co/xr692rSZZ1

Links:

Dr. John Cush RheumNow ( View Tweet)
2017 Prevalence of Psoriatic arthritis (PsA) in Sweden estimated to be 0.34% (range 0.32-0.50% across all sensitivity analyses); lower in males & w/ higher level of education. 0.24% have seen rheumatology care- 32% on b/ts-DMARDs, 41% csDMARDs https://t.co/Jh2WUYVJR2 https://t.co/ZdFVIq2iQ0

Links:

Dr. John Cush RheumNow ( View Tweet)
ARTIS Swedish study of Cancer in RA or PSA pts (~15k pts) starting JAKi vs TNFi. With ~2 yrs F/U, the risk of Cancer (excluding NMSC) was similar betw JAKi and TNFi (HR 0.94; 0.65 to 1.38), but more incident NMSC w/ JAKi (HR 2.12; 1.15 to 3.89) at 2 yrs https://t.co/BiPWF1T0lZ https://t.co/nrmaCGBcce

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 87 pts with isolated Nail Psoriasis noted that 11% went on to have #PsA (concurrently or within 3 years). NP findings were mainly onycholysis in79% and nail pitting in 70% https://t.co/2NynITxe6B https://t.co/qs4uYySjxp

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA: Depressing News on Second- and Later-Line Treatments Most patients with PsA failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated. https://t.co/7tSzoNLVoD https://t.co/3oUM4E38b1

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective study of 490 mod-to-severe psoriasis compared prospectively by exam & US for PsA - 384 w/o arthritis (Silent PSO), 80 non-PSO & 106 w prodromal or active PsA (12.7%). US synovio-enthesitis in 1.8% of controls & 16.1% of silent PSO (p< 0.001) https://t.co/kUdIwLnfYL https://t.co/dgIaOXaJKR

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×